From: Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer
OS
Variables
HR
95% CI
p-value
Initial clinical stage
3.597
1.037–12.480
0.044
ER
3.329
0.296–37.454
0.330
bcl-2
3.027
0.557–16.437
0.200
Triple negative
1.847
0.492–6.935
0.364